Cite
Selective tumor antigen vaccine delivery to human CD169+ antigen-presenting cells using ganglioside-liposomes.
MLA
Affandi, Alsya J., et al. “Selective Tumor Antigen Vaccine Delivery to Human CD169+ Antigen-Presenting Cells Using Ganglioside-Liposomes.” Proceedings of the National Academy of Sciences of the United States of America, vol. 117, no. 44, Nov. 2020, pp. 1–12. EBSCOhost, https://doi.org/10.1073/pnas.2006186117.
APA
Affandi, A. J., Grabowska, J., Olesek, K., Venegas, M. L., Barbaria, A., Ernesto Rodríguez, Mulder, P. P. G., Pijffers, H. J., Ambrosini, M., Kalay, H., O’Toole, T., Zwart, E. S., Kazemier, G., Nazmi, K., Bikker, F. J., Stöckl, J., van den Eertwegh, A. J. M., de Gruijl, T. D., Storm, G., & van Kooyk, Y. (2020). Selective tumor antigen vaccine delivery to human CD169+ antigen-presenting cells using ganglioside-liposomes. Proceedings of the National Academy of Sciences of the United States of America, 117(44), 1–12. https://doi.org/10.1073/pnas.2006186117
Chicago
Affandi, Alsya J., Joanna Grabowska, Katarzyna Olesek, Miguel Lopez Venegas, Arnaud Barbaria, Ernesto Rodríguez, Patrick P. G. Mulder, et al. 2020. “Selective Tumor Antigen Vaccine Delivery to Human CD169+ Antigen-Presenting Cells Using Ganglioside-Liposomes.” Proceedings of the National Academy of Sciences of the United States of America 117 (44): 1–12. doi:10.1073/pnas.2006186117.